Metabolic Solutions Development Company has raised enough money to proceed with a clinical trial of its novel drug candidate that will target type 2 diabetes, the San Francisco Chronicle reports.
The company, which develops therapeutics to treat diabetes and other metabolic disorders, announced this week that it had raised $23.5 million, bringing the total raised since 2006 to $50 million. The funds will allow the company to conduct a Phase 2b double-blind clinical trial with more than 420 patients at 30 planned sites.
MSDC-0160, the drug candidate, would significantly improve the safety...
